Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 14/20 | 0.64 |
| ▸ | IKZF3 | Q9UKT9 | 3/20 | 0.60 |
| ▸ | BRD4 | O60885 | 3/20 | 0.60 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.60 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.60 |
| ▸ | TNF | P01375 | 1/20 | 0.60 |
| ▸ | IL1B | P01584 | 1/20 | 0.60 |
| ▸ | MAP1LC3B | Q9GZQ8 | 4/20 | 0.60 |
| ▸ | STAT3 | P40763 | 1/20 | 0.56 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.54 |
| ▸ | AXL | P30530 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30042744 | 0.96 | CRBN (0.62) | CRBNIKZF3BRD4IKZF1DDB1 | |
| SCHEMBL28909798 | 0.96 | CRBN (0.62) | CRBNIKZF3BRD4IKZF1DDB1 | |
| SCHEMBL17536572 | 0.94 | CRBN (0.67) | CRBNIKZF3BRD4IKZF1DDB1 | |
| SCHEMBL17536561 | 0.92 | CRBN (0.64) | CRBNIKZF3BRD4IKZF1DDB1 | |
| SCHEMBL21596986 | 0.90 | CRBN (0.63) | CRBNIKZF3BRD4IKZF1DDB1 | |
| SCHEMBL30438018 | 0.90 | CRBN (0.63) | CRBNIKZF3BRD4IKZF1DDB1 | |
| SCHEMBL17536570 | 0.89 | CRBN (0.66) | CRBNIKZF3BRD4IKZF1DDB1 | |
| SCHEMBL18105097 | 0.89 | CRBN (0.61) | CRBNIKZF3BRD4IKZF1DDB1 | |
| SCHEMBL16743005 | 0.89 | CRBN (0.61) | CRBNIKZF3BRD4IKZF1DDB1 | |
| SCHEMBL29856007 | 0.89 | CRBN (0.61) | CRBNIKZF3BRD4IKZF1DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019055444-A1 | BET BROMODOMAIN PROTEIN DEGRADERS WITH CLEAVABLE LINKERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-03-21 | — | — | WO | disclosed |
| US-20160058872-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2016-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160058872-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | CRBN, MDM2, UBE2N | CRBN 1/4885IKZF3 248/4885BRD4 464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.